Tag: study

LOS ANGELES, July 23, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

J.D. Power Recognizes Verizon as America’s Most Awarded for Network Quality, an unprecedented 35 Times in a row

Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal antibody, procizumab, in patients with shock caused primarily by cardiogenic events. Shock is a life-threatening condition characterized by a sudden breakdown in circulatory function due to end-stage disease or acute events, which often leads to organ failure. With only symptomatic treatment options available, shock is associated with a high mortality rate of over 50%. The Phase 1b/2a trial is designed to identify a target dose for procizumab in preparation for further clinical development. In addition, the trial will provide signals of efficacy. In a Phase 1 study in healthy volunteers, procizumab was well tolerated.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Inferior Vena Cava IVC Filter Market size & share revenue was valued at approximately USD 895.82 Million in 2024 and is expected to reach USD 974.16 Million in 2025 and is expected to reach around USD 2,094.10 Million by 2034, at a CAGR of 8.88% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott, B. Braun Melsungen AG, Boston Scientific Corporation, Canon Medical Systems, Cardinal Health, Cook, Esaote SpA, General Electric Company, Hologic, Inc., Koninklijke Philips N.V., Samsung Healthcare, Shimadzu Corporation, Siemens Healthcare Private Limited, Stryker, Terumo Europe NV and others.